
Sign up to save your podcasts
Or


By Science History Institute
4.5
9292 ratings
The podcast currently has 365 episodes available.
The most played episodes among Podcast App listeners.

Alexis Pedrick joins Sam Jones and Deboki Chakravarti to bring you an episode from Tiny Matters, an award-winning podcast from the American Chemical Society produced by Multitude. The episode, which originally aired in February 2026, explores the surprising origins and evolution of one of modern medicine's most important tools: the clinical trial. Tiny Matters follows the development of experimental design across centuries to modern-day randomized control trials and the debates about their limitations, trying to answer the question, "How do we know whether a treatment truly works?" Credits Host: Alexis Pedrick Executive Producer: Mariel Carr Senior Producer: Rigoberto Hernandez Resource List Placebo Controls, Exorcisms and the Devil The Eight Wars of Religion (1562–1598) The Emergence of the Randomized, Controlled Trial The Emergence of the Randomized Controlled Trial: Origins to 1980 Streptomycin Treatment of Pulmonary Tuberculosis Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016 Conservative Treatment of Acute Appendicitis: An Overview Most Patients with Appendicitis Can Have Antibiotics as Their First Treatment, Rather than Appendectomy Assessing the Gold Standard—Lessons from the History of RCTs

This episode is a co-production with Lost Women of Science. Agnes Pockels did pioneering work in surface science. Her invention, the Pockels Trough, became the basis for an instrument that helped Katherine Burr Blodgett and Irving Langmuir make discoveries in material science that quietly shape our everyday world. But the way we talk about Agnes's life and work often falls back on familiar tropes about women's domestic roles, assumptions about how science gets done, and what it looked like to do science as a woman in the 19th century. Agnes's story invites us to rethink how we define success for scientists. Is our definition too narrow? And what might we gain if we crack it open a bit wider? Credits Host: Alexis PedrickExecutive Producer: Mariel CarrProducer: Rigoberto Hernandez Additional Reporting: Sophia Levin Art Design: Lily Whear Fact-Checking: Alexandria Attia Sound Design: Ana Tuirán Guests Brigitte Van Tiggelen Brigitte Van Tiggelen is the Science History Institute's director of international affairs, working from the Institute's office in Paris. Trained as both a physicist and a historian, she is the coeditor of Women in Their Element: Selected Women's Contributions to the Periodic System (2019), a volume that brings together more than two decades of research and publication of the life and work of women in science. Donald L. Opitz Donald L. Opitz is a historian of science who teaches in the School of Continuing and Professional Studies and Department of History at DePaul University. He is writing a book that traces the international movement for the advancement of women in agriculture and horticulture from the mid-19th to mid-20th centuries. Petra Mishnik Petra Mischnick was a professor of food chemistry at Technische Universität Braunschweig, Germany. There she founded and ran the Agnes Pockels Student Lab to inspire young children, especially girls, to pursue science. Resource List Kohlstedt, Sally Gregory and Opitz, Don. "Agnes Pockels - Surface Chemist and 'Hausfrau'," The Changing Image of the Sciences. 2002. Pockels, Agnes. "On the Relative Contamination of the Water-Surface by Equal Quantities of Different Substances." Nature, 1892. Sella, Andrea. "Pockels' Trough." Chemistry World, 2015. Tiggelen, Brigitte Van. "Fräulein Agnes Pockels: The Shaping of a 'Forschende Hausfrau'," paper presented at the 24th International Congress of History of Science, Technology, and Medicine. Bergwik, Staffan; Opitz, Donald L.; Tiggelen, Brigitte Van. Domesticity in the Making of Modern Science. 2016. A full transcript is available on our website.

Our producer Rigoberto Hernandez spoke with Robin Marantz, the author of Pandora's Baby: How the First Test Tube Babies Sparked the Reproductive Revolution. She tells us about the history of IVF, from the first known artificial insemination by donor produced in Philadelphia in the 19th century to the scientific race in the 1960s and 1970s that resulted in the first so-called "test-tube baby." Credits Host: Alexis Pedrick Executive Producer: Mariel Carr Producer: Rigoberto Hernandez Associate Producer: Sarah Kaplan Audio Engineer: Samia Bouzid Music by Blue Dot Sessions Resource List Henig, Robin Marantz. Pandora's Baby: How the First Test Tube Babies Sparked the Reproductive Revolution. Cold Spring Harbor Laboratory Press, 2006.

When Rebekah and Evan Lockard's daughter, Naomi, was diagnosed with a devastating ultra-rare genetic disease, they didn't know where to turn. Then they found Terry Pirovolakis, an IT professional who had made a gene therapy for his son with the same disease. But the process of getting Naomi treated has been an uphill battle, full of financial and logistical obstacles. The Lockard's story flips the question we've been asking all season on its head. Instead of wondering, "if we could do something, should we," we're now asking, "if we can do something that helps patients, should we do it at any cost?" And this question isn't for scientists or researchers, it's for the rest of us. Credits Host: Alexis Pedrick Executive Producer: Mariel Carr Producer: Rigoberto Hernandez Associate Producer: Sarah Kaplan Audio Engineer: Samia Bouzid Music by Blue Dot Sessions Resource List Mast, Jason. "A dad built a gene therapy for his son. Can he save other kids, too?" STAT News. Elpida Therapeutics. "Battling SPG50 and changing the world." August 17, 2022. The Jackson Laboratory. Brent, Jonathan R. and Deng, Han-Xiang. "Paving a way to treat spastic paraplegia 50." "AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient." June 28, 2004. "Colorado family pushes for more funding, awareness around rare neurological disorder." August 12, 2024. CBS News Colorado. Naomi's Corner.

Gene therapy is based on a simple-sounding, yet deceptively complicated premise: adding or replacing faulty genes to fix medical problems. A compelling idea that came out of breakthroughs in DNA research, the field grew lightning fast. But the death of teenager Jesse Gelsinger after a gene therapy clinical trial left the public and scientists questioning the field's promise. Why did researchers push ahead with clinical trials despite gene therapy still being in its infancy? What does the Jesse Gelsinger story tell us about the personal risk behind medical breakthroughs? Credits Host: Alexis Pedrick Executive Producer: Mariel Carr Producer: Rigoberto Hernandez Associate Producer: Sarah Kaplan Audio Engineer: Samia Bouzid Music by Blue Dot Sessions Resource List American Experience: The Boy in the Bubble. PBS. Begley, Sharon. "Out of Prison, the 'Father of Gene Therapy' Faces a Harsh Reality: a Tarnished Legacy and an Ankle Monitor." STAT News, July 23, 2018. Cobb, Matthew. As Gods: A Moral History of the Genetic Age. New York: Basic Books, 2022. "C‑SPAN: Paul Gelsinger." C‑SPAN. Gelsinger, Paul L. "Jesse's Intent." Circare. ABC Evening News. Vanderbilt Television News Archive, December 8, 1999. CBS Evening News. Vanderbilt Television News Archive, May 28, 1999. NBC Nightly News Broadcast. Vanderbilt Television News Archive, December 8, 1999. "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy." Georgetown University Library. Rinde, Meir. "The Death of Jesse Gelsinger, 20 Years Later." Science History Institute, June 4, 2019. Stolberg, Sheryl Gay. "The Biotech Death of Jesse Gelsinger." New York Times Magazine, November 28, 1999. "Teen Dies Undergoing Experimental Gene Therapy." Washington Post, September 29, 1999. "The Glimmering Promise of Gene Therapy." MIT Technology Review, November 1, 2006. The NewsHour with Jim Lehrer, 1999-12-08. NewsHour Productions. American Archive of Public Broadcasting (GBH and the Library of Congress), Boston, MA and Washington, DC. Wilson, James . "Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency."
The podcast currently has 365 episodes available.

91,038 Listeners

78,549 Listeners

43,924 Listeners

32,056 Listeners

43,430 Listeners

38,695 Listeners

26,209 Listeners

546 Listeners

12,195 Listeners

6,445 Listeners

16,385 Listeners

297 Listeners

1,321 Listeners

2,306 Listeners

1,639 Listeners